Neurological Outcome After Erythropoietin Treatment for Neonatal Encephalopathy

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

167

Participants

Timeline

Start Date

August 31, 2003

Primary Completion Date

July 31, 2008

Study Completion Date

July 31, 2008

Conditions
Hypoxic-Ischemic Encephalopathy
Interventions
DRUG

recombinant human erythropoietin

r-hu-EPO were administered either 300 U/kg or 500 U/kg, subcutaneously the first time and then intravenously every other day for 2 weeks.

Trial Locations (1)

450052

NICU, the Third Affiliated Hospital, Zhengzhou University, Zhengzhou

All Listed Sponsors
collaborator

Zhengzhou Children's Hospital, China

OTHER

collaborator

Medical University Innsbruck

OTHER

collaborator

Göteborg University

OTHER

lead

Zhengzhou University

OTHER

NCT00808704 - Neurological Outcome After Erythropoietin Treatment for Neonatal Encephalopathy | Biotech Hunter | Biotech Hunter